January 27, 2016
The Recorder
On January 25, 2016, a Delaware federal judge ruled in favor of Finnegan client, Wisconsin Alumni Research Foundation (WARF), concluding that Washington University in St. Louis (WashU) waited too long to stake its claim to a larger share of royalties from sales of a drug to treat kidney disease, Zemplar. WARF and WashU collectively developed one of the patents for the drug and the two parties entered into agreement to collect royalties. WashU raised questions about the agreement in 2001, but waited until 2013 to sue. According to the judge, WARF was transparent about the terms of the agreement and WashU was outside of the applicable statute of limitations to sue. The judge stated, "Therefore, the court must agree with WARF that its actions, inactions, or representations did not prevent [Washington] from timely filing suit." The case was ultimately dismissed.
Award/Ranking
Women in Business Law EMEA Awards 2024: Finnegan Nominated for German Firm of the Year
May 15, 2024
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.